Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.41 |
| ▸ | RAB9A | P51151 | 8/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16154685 | 0.78 | POLB (0.47) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL15907140 | 0.78 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL19848135 | 0.78 | MAPK13 (0.41) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL22883424 | 0.77 | MAPT (0.48) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL6867676 | 0.74 | CHRNB2 (0.45) | NPC1RAB9ASMN1; SMN2MAPTKMT2A | |
| SCHEMBL20253184 | 0.73 | MAPT (0.48) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL19911318 | 0.72 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL18136606 | 0.72 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL19915937 | 0.72 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL23042573 | 0.70 | GAA (0.43) | NPC1RAB9ASMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522910-B2 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) | 2016-12-20 | — | — | US | disclosed |
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | NPC1 3370/4885RAB9A 1864/4885SMN1; SMN2 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.